Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a…
Biotech - From the Top Deck: M&A Check-In - Got Room for Dessert? Yes, But Bring Spoons to Share $ABVX $RCUS $CYTX least likely $VKTX $MDGL https://t.co/uiNvdLTnID
$MDGL IMHO attractive takeover target by BP. LLY could be the potential acquirer based on CEO's commentary last week. Synergistic with their Obesity franchise. - First approved MASH/NASH drug - Established commercial launch - Potential expansion into broader liver disease
$MDGL UBS: Reiterated Buy Based on our analysis of the F4 Outcomes trial and higher likelihood of success, we are raising our PT to $735 (prior $669). We now assign a 60% PoS to the F4 program, up from 20% previously.
$MDGL At a key support area. This zone has acted as a reliable floor on the last three tests, each leading to a significant bounce.
$MDGL Why Madrigal Pharmaceuticals (MDGL) Should Be a Prime Acquisition Target for Big Pharma- - Building a competitor from scratch could take a decade. Buying MDGL takes one deal. - commercial-stage with approved therapy for MASH, a market expected to reach tens of billions of
Biotech names I have been selectively buying on this pullback (seasonality) and because of pullback due to rising yields- $VKTX $BBIO $ABVX $CYTK $AVR $TNGX $ERAS $PCVX $KURA $CRVS $INBX $CELC Few names on my watch list: $AXSM $CTMX $LRMR $MDGL
19 analysts rate MDGL Buy on consensus.
Consensus price target: $685.22 (+57.8% upside from $434.24)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Sibold William John director, President and CEO | Sep 11, 2026 | Sale | 218 | $116.84K |
| Sibold William John director, President and CEO | Sep 11, 2026 | Sale | 120 | $65.57K |
| Sibold William John director, President and CEO | Sep 11, 2026 | Sale | 160 | $86.02K |
| Sibold William John director, President and CEO | Sep 11, 2026 | Sale | 368 | $199.32K |
| Sibold William John director, President and CEO | Sep 11, 2026 | Sale | 1,202 | $652.21K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $958.4M | +432.05% | $-288.28M |
| 2024 | $180.13M | — | $-465.89M |
| 2023 | $0 | — | $-373.63M |
Stock data for MDGL: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics